Median Technologies (STU:4ZG) ROCE % : -951.88% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Median Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Median Technologies's annualized ROCE % for the quarter that ended in Jun. 2024 was -951.88%.

Median Technologies ROCE % Historical Data

The historical data trend for Median Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Technologies ROCE % Chart

Median Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-125.65

-307.81

-130.32

-109.89

-170.95

Median Technologies Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-79.11	-142.40	-253.89	-284.30	-951.88

Median Technologies ROCE % Calculation

Median Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-21.03	/	( ( (34.753 - 23.364)	+	(35.935 - 22.721) )	/ 2 )
	=	-21.03	/	( (11.389	+	13.214)	/ 2 )
	=	-21.03	/	12.3015
	=	-170.95 %

Median Technologies's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-21.898	/	( ( (35.935 - 22.721)	+	(32.91 - 41.523) )	/ 2 )
	=	-21.898	/	( ( 13.214	+	-8.613 )	/ 2 )
	=	-21.898	/	2.3005
	=	-951.88 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Median Technologies (STU:4ZG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Median Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of Median Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Median Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (STU:4ZG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ALMDT:France

Address

1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560

Website

https://www.mediantechnologies.com

Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies Headlines

No Headlines